Hepatic glycogen storage diseases type 0, VI and IX: description of an italian cohort.
Glycogen storage disease
Insulin-resistance
Liver
Nutrition
Nutritional therapy
Obesity
Overweight
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
18
03
2022
accepted:
30
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Glycogen storage disease (GSD) type 0, VI and IX are inborn errors of metabolism involving hepatic glycogen synthesis and degradation. We performed a characterization of a large Italian cohort of 30 patients with GSD type 0a, VI, IXa, IXb and IXc. A retrospective evaluation of genetical, auxological and endocrinological data, biochemical tests, and nutritional intakes was assessed. Eventual findings of overweight/obesity and insulin-resistance were correlated with diet composition. Six GSD-0a, 1 GSD-VI, and 23 GSD-IX patients were enrolled, with an age of presentation from 0 to 72 months (median 14 months). Diagnosis was made at a median age of 30 months, with a median diagnostic delay of 11 months and a median follow-up of 66 months. From first to last visit, patients gained a median height of 0.6 SDS (from - 1.1 to 2.1 SDS) and a median weight of 0.5 SDS (from - 2.5 to 3.3 SDS); mean and minimal glucose values significant improved (p < 0.05). With respect to dietary intakes, protein intake (g/kg) and protein intake (g/kg)/RDA ratio directly correlated with the glucose/insulin ratio (p < 0.05) and inversely correlated with HOMA-IR (Homeostasis model assessment of insulin resistance, p < 0.05), BMI SDS (p < 0.05) and %ibw (ideal body weight percentage, p < 0.01). A prompt establishment of specific nutritional therapy allowed to preserve growth, improve glycemic control and prevent liver complication, during childhood. Remarkably, the administration of a high protein diet appeared to have a protective effect against overweight/obesity and insulin-resistance.
Sections du résumé
BACKGROUND
Glycogen storage disease (GSD) type 0, VI and IX are inborn errors of metabolism involving hepatic glycogen synthesis and degradation. We performed a characterization of a large Italian cohort of 30 patients with GSD type 0a, VI, IXa, IXb and IXc. A retrospective evaluation of genetical, auxological and endocrinological data, biochemical tests, and nutritional intakes was assessed. Eventual findings of overweight/obesity and insulin-resistance were correlated with diet composition.
RESULTS
Six GSD-0a, 1 GSD-VI, and 23 GSD-IX patients were enrolled, with an age of presentation from 0 to 72 months (median 14 months). Diagnosis was made at a median age of 30 months, with a median diagnostic delay of 11 months and a median follow-up of 66 months. From first to last visit, patients gained a median height of 0.6 SDS (from - 1.1 to 2.1 SDS) and a median weight of 0.5 SDS (from - 2.5 to 3.3 SDS); mean and minimal glucose values significant improved (p < 0.05). With respect to dietary intakes, protein intake (g/kg) and protein intake (g/kg)/RDA ratio directly correlated with the glucose/insulin ratio (p < 0.05) and inversely correlated with HOMA-IR (Homeostasis model assessment of insulin resistance, p < 0.05), BMI SDS (p < 0.05) and %ibw (ideal body weight percentage, p < 0.01).
CONCLUSION
A prompt establishment of specific nutritional therapy allowed to preserve growth, improve glycemic control and prevent liver complication, during childhood. Remarkably, the administration of a high protein diet appeared to have a protective effect against overweight/obesity and insulin-resistance.
Identifiants
pubmed: 35854365
doi: 10.1186/s13023-022-02431-5
pii: 10.1186/s13023-022-02431-5
pmc: PMC9295101
doi:
Substances chimiques
Insulins
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
285Informations de copyright
© 2022. The Author(s).
Références
Mol Genet Metab. 2006 Apr;87(4):284-8
pubmed: 16337419
Arch Med Sci. 2019 Feb 18;17(2):304-313
pubmed: 33747265
Acta Endocrinol (Buchar). 2019 Oct-Dec;15(4):526-530
pubmed: 32377253
J Pediatr Pharmacol Ther. 2019 Sep-Oct;24(5):421-430
pubmed: 31598106
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur J Pediatr. 1990 Jan;149(4):268-71
pubmed: 2303074
Mol Genet Metab. 2013 Jun;109(2):179-82
pubmed: 23578772
Eur J Pediatr. 2020 Mar;179(3):405-413
pubmed: 31768638
J Sport Health Sci. 2021 Dec;10(6):675-689
pubmed: 34237456
Eur J Nutr. 2021 Aug;60(5):2435-2447
pubmed: 33145643
World J Gastroenterol. 2007 May 14;13(18):2541-53
pubmed: 17552001
BBA Clin. 2016 Feb 27;5:85-100
pubmed: 27051594
J Int Med Res. 2020 Aug;48(8):300060520936857
pubmed: 32779500
J Endocrinol Invest. 2006 Jul-Aug;29(7):581-93
pubmed: 16957405
JIMD Rep. 2020 Feb 25;53(1):39-44
pubmed: 32395408
JAMA Pediatr. 2019 Jun 1;173(6):597-598
pubmed: 30933264
J Inherit Metab Dis. 2007 Oct;30(5):722-34
pubmed: 17705025
Front Biosci. 1999 Sep 15;4:D618-41
pubmed: 10487978
J Pediatr Endocrinol Metab. 2017 Apr 1;30(4):459-462
pubmed: 28245189
Genet Med. 2019 Apr;21(4):772-789
pubmed: 30659246
Gastroenterology. 2017 Feb;152(3):571-585.e8
pubmed: 27765690
JIMD Rep. 2017;37:63-72
pubmed: 28283841
Mol Genet Metab. 2014 Nov;113(3):171-6
pubmed: 25266922
J Pediatr Gastroenterol Nutr. 2012 Jul;55(1):90-2
pubmed: 21857251
Ann Transl Med. 2018 Dec;6(24):474
pubmed: 30740405
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034